Artificial Intelligence (AI) transforms different industries as an important investment theme in 2025. The ability of technology to automate complex workflows and improve productivity is seen as a game changer for the next generation of innovation.
Perhaps the most promising AI application is the potential to bring about a revolution in medicine by speeding up the drug discharge process to deliver more effective therapies. Various biotechnology companies embrace these advanced capacities to unlock new growth opportunities.
Here are three fantastic Biotech shares Use the power of AI that could be a great addition to your portfolio.
Image source: Getty images.
Abbvie(NYSE: ABBV) is a leader in biofharmaceuticals with a product portfolio that includes multiple therapeutic areas, including a strong focus on immunology diseases and a growing franchise on oncology and neurosciences.
The share gathered sharply after a better than expected winning report in the fourth quarter, propelled by a strong sale of Blockbuster autoimmune drugs Skyrizi and Rinvoq-seen as improved successors of the Legacy Humira. The management also expects operational and finance momentum, aimed at 2025 adapted profit per share (EPS) between $ 12.12 and $ 12.32, which represents a solid increase of 21% at the center of the result of 2024.
Optimism surrounds ABBVIE’s artificial intelligence strategy, which is aimed at Abbvie Research and Development Convergence Hub (Arch) and is linked to an extensive pipeline for medicine candidate. This platform enables scientists to extract large-scale data, to promote AI medicine discovery and to optimize the design of the medicine. By integrating AI and Machine learning In the R&D process, the company may want to reduce the traditional timeline of 10 to 15 years for developing new medicines in two.
In the end, Abbvie seems to have all the documents in the long term to reward shareholders.
A winning approach of investing can sometimes be as simple as sticking to a proven winner. That’s great news for shareholders of Gilead Sciences(Nasdaq: Gild)Because the share has risen by 26% in the past year and reached the highest level in almost a decade.
This biotech giant is recognized for its antiviral therapies, so that global markets lead to HIV and hepatitis C treatments and at the same time diversify impressive progress into areas such as oncology. The income from the third quarter of the company in the third quarter of 2024 exceeded the estimates of Wall Street in the midst of a strong demand in his product portfolio. Management was projected trust by increasing its income from the entire year and EPS target white, with reference to a positive market traction for Livdelzi, which treats primary galcholangitis (PBC), a debilitating liver disease.
Gilead’s prospects in 2025 is promising, with several late phase clinical programs awaiting data reading. In January, the company expanded its partnership with Cognizant to develop adapted generative AI solutions that are aimed at improving business efficiency. A separate collaboration with private terray therapeutics uses the AI-driven “TNOVA Drug Discovery Platform of the Biotech Company”, where Gilead obtains an exclusive option to commercialize potential products developed through the program.
These initiatives position Gilead to maintain its competitive advantage in the rapidly evolving biotechnology landscape. The ability of the company to keep innovating makes Gilead a compelling shares to possess in what could be a milestone year.
Unlike ABBVIE and Gilead Sciences shares, who have been strong artists to start 2025, Modern(Nasdaq: mrna) stands out like a turnaround opportunity.
The company, recognized for its groundbreaking role in the development of MRNA vaccine, has difficulty managing the decreasing demand for COVID-19 immunisations. Market problems with regard to Moderna’s ability to produce a new blockbuster medication have led the shares to fall with a disastrous 64% in the past year. Nevertheless, this volatility can offer investors a mandatory buying option in a beaten industrial leader, which could be the case here.
Moderna is moving forward with exciting therapeutic prospects, including new vaccines for norovirus and cytomegalovirus (CMV). In January, the company received a prize of $ 590 million from the US government to complete a late stage of an H5N1-Aviaire Influenza vaccine.
The company has set an ambitious goal to obtain 10 new product goods inspections within three years, in which artificial intelligence plays a crucial role. Moderna is building an extensive digital platform and cloud-native infrastructure and works together with technical leaders such as OpenAI and IBM to integrate AI into its value chain and scale mrna technology.
Investors trust Moderna’s ability to get back on the right track with stronger growth, can consider the current share price as an attractive access point for a long -term party.
Have you ever had the feeling that you missed the boat to buy the most successful shares? Then you want to hear this.
In rare cases, our expert team of analysts gives one “Double Down” Recommendation for companies that they think is about to pop. If you are worried that you have already missed your chance to invest, this is the best time to buy before it is too late. And the figures speak for themselves:
Nvidia:If you invested $ 1,000 when we doubled in 2009,You would have $ 323,686!**
Apple: If you invested $ 1,000 when we doubled in 2008, You would have $ 44,026!**
Netflix: If you invested $ 1,000 when we doubled in 2004, You would have $ 545,283!**
At the moment we are publishing “Double Down” warnings for three incredible companies, and there may not be a different chance soon.
And Victor has no position in one of the aforementioned shares. The Motley Fool has positions and recommends Abbvie and Gilead Sciences. The Motley Fool recommends Moderna. The colorful fool has one disclosure policy.
